| Dr Jon Peter Lensmeyer, MD | |
|
1206 Washington Ave, Port Huron, MI 48060-3555 | |
| (810) 984-3100 | |
| (810) 984-1656 |
| Full Name | Dr Jon Peter Lensmeyer |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 31 Years |
| Location | 1206 Washington Ave, Port Huron, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598723330 | NPI | - | NPPES |
| 104271825 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 4301077044 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mclaren Port Huron | Port huron, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northpointe Ob-gyn Pc | 6204921257 | 4 |
News Archive
The benefits of electronic health records (EHRs) may become more widely available to children through an EHR format for children's health care announced today by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ) and Centers for Medicare & Medicaid Services (CMS).
The prognosis of ovarian cancer is poor, with an estimated five-year survival of only 40% for advanced disease, the stage at which most ovarian carcinomas are diagnosed.
Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA.
In this New York Times opinion piece, columnist Tina Rosenberg examines a global rise in cholera cases, writing, "The World Health Organization estimates that there are between three million and five million cases of cholera each year, and between 100,000 and 120,000 deaths. New and more virulent strains are emerging in Asia and Africa, and the WHO says that global warming creates even more hospitable conditions for the disease."
Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.
› Verified 8 days ago
| Entity Name | Northpointe Ob-gyn Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629107628 PECOS PAC ID: 6204921257 Enrollment ID: O20071005000031 |
News Archive
The benefits of electronic health records (EHRs) may become more widely available to children through an EHR format for children's health care announced today by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ) and Centers for Medicare & Medicaid Services (CMS).
The prognosis of ovarian cancer is poor, with an estimated five-year survival of only 40% for advanced disease, the stage at which most ovarian carcinomas are diagnosed.
Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA.
In this New York Times opinion piece, columnist Tina Rosenberg examines a global rise in cholera cases, writing, "The World Health Organization estimates that there are between three million and five million cases of cholera each year, and between 100,000 and 120,000 deaths. New and more virulent strains are emerging in Asia and Africa, and the WHO says that global warming creates even more hospitable conditions for the disease."
Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jon Peter Lensmeyer, MD 1206 Washington Ave, Port Huron, MI 48060-3555 Ph: (810) 984-3100 | Dr Jon Peter Lensmeyer, MD 1206 Washington Ave, Port Huron, MI 48060-3555 Ph: (810) 984-3100 |
News Archive
The benefits of electronic health records (EHRs) may become more widely available to children through an EHR format for children's health care announced today by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ) and Centers for Medicare & Medicaid Services (CMS).
The prognosis of ovarian cancer is poor, with an estimated five-year survival of only 40% for advanced disease, the stage at which most ovarian carcinomas are diagnosed.
Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA.
In this New York Times opinion piece, columnist Tina Rosenberg examines a global rise in cholera cases, writing, "The World Health Organization estimates that there are between three million and five million cases of cholera each year, and between 100,000 and 120,000 deaths. New and more virulent strains are emerging in Asia and Africa, and the WHO says that global warming creates even more hospitable conditions for the disease."
Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.
› Verified 8 days ago
Dr. Peter Y Tseng, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1221 Pine Grove Ave, Port Huron, MI 48060 Phone: 810-985-2663 Fax: 810-989-3174 | |
Kyu Hwang, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2425 Military St, Building 5, Port Huron, MI 48060 Phone: 810-984-1535 Fax: 810-984-8320 | |
Dr. Eric James Hartman, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1313 Stone St, Port Huron, MI 48060 Phone: 810-984-3181 Fax: 810-985-5196 | |
Dr. Karen Louise Niver, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1206 Washington Ave, Port Huron, MI 48060 Phone: 810-984-3100 Fax: 810-984-1656 | |
David A Bailey, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2603 Electric Ave Ste 2, Port Huron, MI 48060 Phone: 810-329-3333 Fax: 810-329-1199 | |
Dr. Amanda Hurtubise, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1206 Washington Ave, Port Huron, MI 48060 Phone: 810-984-3100 Fax: 810-984-1656 | |
Dr. Zeenat Anwar, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 3820 Gratiot Ave, Port Huron, MI 48060 Phone: 810-987-2550 Fax: 810-987-7560 |